Respiratory specialist Circassia Pharmaceuticals PLC (LON:CIR) will later Monday announce the US launch of a new product for chronic obstructive pulmonary disease (COPD), describing the landmark as a “major strategic milestone”.
It is using the American College of Chest Physicians' CHEST Annual Meeting in New Orleans as the springboard for Duaklir, which will be sold alongside Tudorza by a dedicated COPD workforce.
Duaklir is a long-acting treatment that comes in powder form and is administered using an inhaler.
The medication is a LAMA/LABA formulation, meaning it uses the muscarinic antagonist, aclidinium bromide, and the beta agonist, formoterol fumarate.
The market for these combination treatments is growing strongly in the States.
"The US launch of Duaklir represents a major strategic milestone for Circassia, significantly boosting our portfolio of marketed respiratory products and strengthening our offering of COPD treatments alongside our aclidinium monotherapy, Tudorz,” said Steve Harris chief executive, Steve Harris.
COPD is a progressive and life-threatening lung disease, which affects around 11mln Americans.
Circassia is a specialty pharma company focused on treating patients with respiratory diseases.
It has two other products on the market: NIOX, which is used to help manage asthma, and the aforementioned Tudorza.
It has several other asthma and COPD treatments in its pipeline, as well as AirNOvent – a portable system that uses electricity to make nitric oxide which is used to dilate blood vessels in the lungs.